Related Experiment Videos
Hypertensives who cannot get proper antihypertensive treatment
Insights
Hypertension treatment is crucial for preventing strokes but is often unavailable in developing nations, especially in Africa and the Caribbean. Urgent action is required from global health organizations and the pharmaceutical industry to address this critical gap in care.
Area of Science:
- Public Health
- Cardiovascular Medicine
- Global Health Disparities
Background:
- Hypertension is a prevalent condition in developing countries, with significant impact in regions like Africa and the Caribbean.
- Antihypertensive therapies are proven effective in stroke prevention, a major complication of uncontrolled high blood pressure.
Purpose of the Study:
- To highlight the critical unmet need for antihypertensive medications in developing regions.
- To call for collaborative action from international hypertension societies and the pharmaceutical sector to improve treatment accessibility.
Main Methods:
- This study is a review and analysis of the current state of hypertension management in developing countries.
- It synthesizes existing data on drug availability and treatment gaps.
Main Results:
- Essential antihypertensive drugs, even the most affordable options, are frequently unavailable in many developing countries.
- This lack of access results in a substantial number of patients not receiving necessary, life-saving treatment.
Conclusions:
- There is a major shortfall in the provision of antihypertensive treatment in developing nations.
- Coordinated efforts by the International Society of Hypertension, World Hypertension League, European and American Societies of Hypertension, and the pharmaceutical industry are essential to rectify this situation.
Abstract:
Hypertension is common in developing countries particularly in Africa and the Caribbean. Antihypertensive treatment has been validated as effective in preventing strokes but often even the cheapest antihypertensive drugs are unavailable. This means that a large number of patients are not receiving the treatment that they need. Action is needed by the International Society of Hypertension, the World Hypertension League, the European and American Societies of Hypertension and the pharmaceutical industry to correct this major shortfall of treatment.